Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions

Kao, Hsiang‐Fong; Lou, Pei‐Jen

doi:10.1002/hed.25930

Cited by 47 publications

(55 citation statements)

References 92 publications

(152 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The monoclonal anti-EGFR antibody cetuximab shows modest long-term benefit in a small percentage of HNSCC patients 12 . The overall survival rate can be further improved by the immune checkpoint inhibitors pembrolizumab and nivolumab, which block PD-1 signaling, but only a fraction of patients with advanced HNSCC still exhibit significant therapeutic responses 13 .…”

Section: Introductionmentioning

confidence: 99%

The potential role of YAP in head and neck squamous cell carcinoma

Shin

Kim

2020

Exp Mol Med

View full text Add to dashboard Cite

The transcriptional cofactor YAP and its inhibitory regulators, Hippo kinases and adapter proteins, constitute an evolutionarily conserved signaling pathway that controls organ size and cell fate. The activity of the Hippo-YAP pathway is determined by a variety of intracellular and intercellular cues, such as cell polarity, junctions, density, mechanical stress, energy status, and growth factor signaling. Recent studies have demonstrated that YAP can induce the expression of a set of genes that allow cancer cells to gain a survival advantage and aggressive behavior. Comprehensive genomic studies have revealed frequent focal amplifications of the YAP locus in human carcinomas, including head and neck squamous cell carcinoma (HNSCC). Moreover, FAT1, which encodes an upstream component of Hippo signaling, is one of the most commonly altered genes in HNSCC. In this review, we discuss the causes and functional consequences of YAP dysregulation in HNSCC. We also address interactions between YAP and other oncogenic drivers of HNSCC.

show abstract

Section: Introductionmentioning

confidence: 99%

The potential role of YAP in head and neck squamous cell carcinoma

Shin

Kim

2020

Exp Mol Med

View full text Add to dashboard Cite

show abstract

“…In recent years, immune checkpoint inhibitors (ICIs), such as nivolumab and pembrolizumab, have shown certain potential in the treatment of HNSCC ( 21 , 22 ). However, primary resistance to ICIs emerges in the majority of patients, and the benefits of this therapy is therefore suboptimal ( 23 ) compared with the anti-programmed death-1 monoclonal antibody ( 24 , 25 ). Therefore, it is particularly important to identify novel predictive biomarkers to improve the screening of patients who can benefit from ICI treatment.…”

Section: Introductionmentioning

confidence: 99%

The clinical significance of apolipoprotein L1 in head and neck squamous cell carcinoma

Zhong¹,

Chen

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Approximately 500,000 new head and neck squamous cell carcinoma (HNSCC) cases are detected every year around the world, and its incidence ranks sixth among all cancer types globally. Among these cases, oral squamous cell carcinoma (OSCC) and laryngeal squamous cell carcinoma (LSCC) are HNSCC subtypes with high incidence rates, especially in China. The present study examines the association between the apolipoprotein L1 (APOL1) mRNA and protein expression and clinical parameters in HNSCC. The two most common types (oral and larynx) of HNSCC were selected for subgroup analyses. Immunohistochemistry (IHC) was used to detect APOL1 protein expression levels in HNSCC clinical specimens. It was demonstrated that APOL1 protein expression in 221 cases of HNSCC was higher compared with that in normal tissues. Consistent upregulation of APOL1 protein was also found in subgroups of OSCC and LSCC. Through mining the ArrayExpress, The Cancer Genome Atlas and the Gene Expression Omnibus databases, microarrays and RNA sequencing data for HNSCC were retrieved, which were used to analyze APOL1 mRNA expression levels. The results showed that APOL1 expression was higher in both OSCC and LSCC subtypes, as well as in HNSCC, compared with that in non-cancerous squamous epithelium. The summary receiver operating characteristic analysis showed that APOL1 had potential as a diagnostic biomarker for HNSCC, OSCC and LSCC. Thus, upregulation of APOL1 may contribute to the tumorigenesis of HNSCC.

show abstract

“…In immunotherapy, host immune system cells recognize cancer cells as foreign, triggering destruction mechanisms to eliminate the target cells [ 97 ]. Importantly, cancer cells activate different mechanism to promote self-survival, including immune escape, as well as T-cell exhaustion [ 98 ]. One of the key mechanisms of cancer immune escape is the activation of programmed death-1 or PD-1/PD-L1 signaling pathway [ 65 , 89 ].…”

Section: Human Papillomavirusmentioning

confidence: 99%

Meet the Insidious Players: Review of Viral Infections in Head and Neck Cancer Etiology with an Update on Clinical Trials

2021

View full text Add to dashboard Cite

Head and neck cancers (HNC) occur in the upper aerodigestive tract and are among the most common cancers. The etiology of HNC is complex, involving many factors, including excessive tobacco and alcohol consumption; over the last two decades, oncogenic viruses have also been recognized as an important cause of HNC. Major etiological agents of nasopharynx carcinoma and oropharyngeal carcinoma include Epstein-Barr virus (EBV) and human papillomaviruses (HPVs), both of which are able to interfere with cell cycle control. Additionally, the association of hepatitis C and hepatitis B infection was observed in oral cavity, oropharyngeal, laryngeal, and nasopharyngeal cancers. Overall prognoses depend on anatomic site, stage, and viral status. Current treatment options, including radiotherapy, chemotherapy, targeted therapies and immunotherapies, are distributed in order to improve overall patient prognosis and survival rates. However, the interplay between viral genome sequences and the health, disease, geography, and ethnicity of the host are crucial for understanding the role of viruses and for development of potential personalized treatment and prevention strategies. This review provides the most comprehensive analysis to date of a vast field, including HNC risk factors, as well as viral mechanisms of infection and their role in HNC development. Additionally, currently available treatment options investigated through clinical practice are emphasized in the paper.

show abstract

Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions

Cited by 47 publications

References 92 publications

The potential role of YAP in head and neck squamous cell carcinoma

The potential role of YAP in head and neck squamous cell carcinoma

The clinical significance of apolipoprotein L1 in head and neck squamous cell carcinoma

Meet the Insidious Players: Review of Viral Infections in Head and Neck Cancer Etiology with an Update on Clinical Trials

Contact Info

Product

Resources

About